Cognitive Dysfunction in Chronic and Persistent Immune Thrombocytopenia

Inclusion Criteria: * Adults aged ≥ 18 years * A clinical diagnosis of persistent or chronic ITP, as defined by a history of platelet counts \<50 x 109/L on two occasions in the preceding 3 to 12 months or \>12 months, respectively, and documented response to at least 1 prior ITP-directed therapy. ITP-directed therapies include corticosteroids, intravenous immune globulin, Rho(D) immune globulin, splenectomy, thrombopoietin receptor agonists, and fostamatinib. Other qualifying agents used for the treatment of ITP are permissible with approval of the principal investigator. * Ability to follow instructions in English. Exclusion Criteria: * Pre-existing diagnosis of cognitive impairment from dementia, stroke, or other neurologic disease. * Active psychiatric disorder, defined as uncontrolled major depression, schizophrenia, severe anxiety, or active alcohol or drug abuse. * Active malignancy, requiring or likely to require chemotherapeutic or surgical treatment, except for non-melanoma skin cancer. * Brain tumor or cranial surgery within the past year. * Significant hearing or vision impairment that would preclude the ability to complete neurocognitive testing via a virtual platform.